Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

Immune-checkpoint blocking antibodies have demonstrated objective antitumor responses in multiple tumor types including melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC). In melanoma, an increase in overall survival has been demonstrated with anti-CTLA-4 and PD-1 inhibition....

Full description

Bibliographic Details
Main Authors: Heinzerling, Lucie, Ott, Patrick A., Hodi, F. Stephen, Husain, Aliya N., Tajmir-Riahi, Azadeh, Tawbi, Hussein, Pauschinger, Matthias, Gajewski, Thomas F., Lipson, Evan J., Luke, Jason J.
Format: Online
Language:English
Published: BioMed Central 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986340/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986340/

Similar Items